• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD.

作者信息

Kutsch Nadine, Gödel Philipp, Voltin Conrad-Amadeus, Kobe Carsten, Hallek Michael, Scheid Christof, Borchmann Peter, Holtick Udo

机构信息

Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Germany.

Center for Integrated Oncology Aachen Bonn Köln Düsseldorf (CIO ABCD), Cologne, Germany.

出版信息

Hemasphere. 2022 Jun 16;6(7):e735. doi: 10.1097/HS9.0000000000000735. eCollection 2022 Jul.

DOI:10.1097/HS9.0000000000000735
PMID:35733532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9205416/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c9b/9205416/2187d3323174/hs9-6-e735-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c9b/9205416/2187d3323174/hs9-6-e735-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c9b/9205416/2187d3323174/hs9-6-e735-g001.jpg

相似文献

1
Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD.慢性肠道和肺部移植物抗宿主病患者安全给予CD19导向的嵌合抗原受体T细胞后复发的弥漫性大B细胞淋巴瘤持续缓解
Hemasphere. 2022 Jun 16;6(7):e735. doi: 10.1097/HS9.0000000000000735. eCollection 2022 Jul.
2
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病经CD19嵌合抗原受体T细胞（CAR-T）治疗后的维持治疗
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):495-501. doi: 10.3760/cma.j.issn.0253-2727.2020.06.011.
3
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].CD19嵌合抗原受体T细胞治疗22例B细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
4
Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.CD19嵌合抗原受体T细胞治疗11例复发/难治性B细胞淋巴瘤患者的疗效和安全性：一项单中心研究
Ann Transl Med. 2020 Sep;8(17):1048. doi: 10.21037/atm-20-4363.
5
Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.基于4-1BB的CD19靶向嵌合抗原受体T细胞（CAR-T）疗法治疗复发或难治性套细胞淋巴瘤后的持续缓解
Onco Targets Ther. 2020 Nov 25;13:12163-12168. doi: 10.2147/OTT.S280535. eCollection 2020.
6
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
7
A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma.一种新型的显性负性PD-1武装抗CD19嵌合抗原受体T细胞对难治性/复发性B细胞淋巴瘤安全有效。
Transl Oncol. 2021 Jul;14(7):101085. doi: 10.1016/j.tranon.2021.101085. Epub 2021 Apr 1.
8
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.采用 RV-SFG.CD19.CD28.4-1BBzeta 逆转录病毒载体转导的 T 淋巴细胞治疗复发或难治性 CD19+淋巴组织疾病患者的单中心 I/II 期临床试验方案。
BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.
9
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
10
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

本文引用的文献

1
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.靶向CD19的嵌合抗原受体T细胞治疗难治性系统性红斑狼疮
N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725.
2
Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive Therapy.氟代脱氧葡萄糖 F18 用于评估急性肠移植物抗宿主病和预测对免疫抑制治疗的反应。
Transplant Cell Ther. 2021 Jul;27(7):603-610. doi: 10.1016/j.jtct.2021.04.011. Epub 2021 Apr 25.
3
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
4
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.CD19靶向嵌合抗原受体修饰T细胞治疗后的晚期事件
Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13.
5
B cells in chronic graft-versus-host disease.慢性移植物抗宿主病中的 B 细胞。
Hum Immunol. 2019 Jun;80(6):393-399. doi: 10.1016/j.humimm.2019.03.003. Epub 2019 Mar 5.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Posttransplant chimeric antigen receptor therapy.移植后嵌合抗原受体治疗。
Blood. 2018 Mar 8;131(10):1045-1052. doi: 10.1182/blood-2017-08-752121. Epub 2018 Jan 22.
8
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.